Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a US-based clinical-stage biopharmaceutical company, announced on Friday that it has named Steve Sabus as its new chief commercial officer, effective 5 December 2022.
In the new role, Sabus will manage all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy.
Sabus has over 30 years of commercial experience launching drugs and building sales and marketing organisations within the biopharmaceutical industry. He has held the position of chief commercial officer at Turning Point Therapeutics. He has served in senior commercial roles at Astellas Pharma for over 15 years, most recently serving as the head of Oncology. He has worked for 16 years at Johnson & Johnson in commercial roles of increasing responsibility.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation